IRVINE, Calif.—Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eyecare, announced that Xemvy (lotilaner ophthalmic solution) 0.25% is now available at pharmacies nationwide for prescription. As reported in VMAIL, the U.S. Food and Drug Administration (FDA) approved Xdemvy on July 24, 2023, for the treatment of Demodex blepharitis. “We are delighted that within weeks of FDA approval, Xdemvy is now available to millions of patients with Demodex blepharitis,” said Bobak Azamian, MD, PhD, chief executive officer and chairman of Tarsus.

“The efforts of our team have created incredible interest in Xdemvy, the first and only approved solution for this highly prevalent disease. I’m so appreciative of our team and our partners who’ve worked diligently to bring this product to eyecare providers and patients quickly and seamlessly following regulatory approval. We are proud to introduce Xdemvy to the eyecare community and look forward to its potential to significantly change the way this disease is treated,” Dr. Azamian said.


Xdemvy is the only FDA approved treatment to directly target Demodex mites, the root cause of Demodex blepharitis. Demodex blepharitis is characterized by redness, inflammation, missing or misdirected eyelashes, itching along the eyelid base and the presence of collarettes. Xdemvy is a prescription eye drop that is administered with one drop in each eye twice daily (approximately 12 hours apart) for six weeks.

To learn more about Xdemy, including full prescribing Information, click here.